doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
32507236	7	58	gly	AZGP1	1116:1120	arg1	the glycan structures	AZGP1			the glycan structures	PUBTATOR		AZGP1	563		We further compared the glycan structures of salivary AZGP1 from lung cancer group and control group.
34070741	4	36	gly	glycosylated	855:866	arg1	partially glycosylated (N220Q) Kv3.1b	partially glycosylated (N220Q) Kv3.1b				Cterm		Kv3.1b			We showed that caudal primary (CaP) motor neurons of zebrafish spinal cord transiently expressing fully glycosylated (WT) Kv3.1b have stereotypical morphology, while CaP neurons expressing partially glycosylated (N220Q) Kv3.1b showed severe maldevelopment with incomplete axonal branching and extension around the ventral musculature.
34070741	4	77	gly	glycosylated	760:771	arg1	fully glycosylated (WT) Kv3.1b	fully glycosylated (WT) Kv3.1b				Cterm		Kv3.1b			We showed that caudal primary (CaP) motor neurons of zebrafish spinal cord transiently expressing fully glycosylated (WT) Kv3.1b have stereotypical morphology, while CaP neurons expressing partially glycosylated (N220Q) Kv3.1b showed severe maldevelopment with incomplete axonal branching and extension around the ventral musculature.
34255124	0	13	gly	synthesis	50:58	arg1	Lactiplantibacillus plantarum VAL6			Lactiplantibacillus plantarum VAL6	Lactiplantibacillus plantarum VAL6		AminoAcid			VAL6	Expression of genes involved in exopolysaccharide synthesis in Lactiplantibacillus plantarum VAL6 under environmental stresses.
32928385	1	31	gly	glycoprotein	202:213	arg1	Recombinant human erythropoietin	Recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Recombinant human erythropoietin (rhEPO) is a glycoprotein that acts as the main hormone involved in regulating red blood cell production to treat anemia caused by chronic kidney disease or chemotherapy.
33551170	8	125	gly	GlyCAM-1	1523:1530	arg1	the glycans	GlyCAM-1			the glycans	PUBTATOR		GlyCAM-1	282430		The degree of fucosylation ranged from 44.8 to 73.3% between cows, and this variation was mainly attributed to the glycans of GlyCAM-1.
32473217	5	47	gly	TFP	1361:1363	arg1	monosaccharide composition	TFP			monosaccharide composition	OGER		TFP	Q9HCM9		High performance liquid chromatography, Fourier-transform infrared spectroscopy, Carbon-13 nuclear magnetic resonance, scanning electron microscopy, atomic force microscopy, and Congo red results indicated that the treatment could break down the polysaccharide chains, hinder the aggregation, and improve the conformation flexibility of the TFP molecules without changing the primary structure and monosaccharide composition of TFP.
34661088	0	55	gly	N-glycosylation	14:28	arg1	SARS-CoV-2 spike protein	SARS-CoV-2 spike protein				PUBTATOR		spike protein	43740568		The effect of N-glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor.
33006278	10	33	gly	moieties	1705:1712	arg1	the heparosan chain	chain			moieties	OGER		chain	Q9Y251		This analytical tool could be applied towards heparosan chain mapping and analysis of unnatural sugar moieties in the heparosan chain.
33973638	3	43	gly	C-type	495:500	arg1	Lectin-galC1	C-type			Lectin-galC1	Cterm		C-type			Using the Drosophila neuromuscular junction (NMJ) as a model glutamatergic synapse, we identify a new Ca2+-binding (C-type) lectin, Lectin-galC1 (LGC1), which modulates presynaptic function and neurotransmission strength.
33973638	3	45	gly	Ca2+-binding	481:492	arg1	Lectin-galC1	Ca2			Lectin-galC1	OGER		Ca2	P00918		Using the Drosophila neuromuscular junction (NMJ) as a model glutamatergic synapse, we identify a new Ca2+-binding (C-type) lectin, Lectin-galC1 (LGC1), which modulates presynaptic function and neurotransmission strength.
32507236	5	16	gly	AZGP1	803:807	arg1	The isomeric glycan structures	AZGP1			The isomeric glycan structures	PUBTATOR		AZGP1	563		The isomeric glycan structures of AZGP1 in these spots were systematically characterized both at composition level and at structure level.
33551170	7	26	gly	pool	1215:1218	arg1	milk protein	milk protein			pool	PUBTATOR		milk protein	281099		Overall, approximately 60% of the N-glycan pool in milk protein was sialylated, or fucosylated, or both; GlyCAM-1 contributed approximately 78% of the total number of glycans in the overall whey protein N-linked glycan pool.
33551170	7	76	gly	protein	1228:1234	arg1	the N-glycan pool	milk protein			the N-glycan pool	PUBTATOR		milk protein	281099		Overall, approximately 60% of the N-glycan pool in milk protein was sialylated, or fucosylated, or both; GlyCAM-1 contributed approximately 78% of the total number of glycans in the overall whey protein N-linked glycan pool.
33551170	1	16	gly	glycoprotein	360:371	arg1	GlyCAM-1	GlyCAM-1				PUBTATOR		GlyCAM-1	282430		In bovine milk serum, the whey proteins with the highest N-glycan contribution are lactoferrin, IgG, and glycosylation-dependent cellular adhesion molecule 1 (GlyCAM-1); GlyCAM-1 is the dominant N-linked glycoprotein in bovine whey protein products.
32804173	6	47	gly	glycoproteins	824:836	arg1	ribonuclease B	ribonuclease B				Cterm		ribonuclease B			We evaluated this method with reduced and permethylated glycans derived from model glycoproteins fetuin and ribonuclease B (RNase B), and then implemented it to human blood serum to generate C18 and PGC column-based isomeric glycan libraries.
33445487	1	22	gly	glycoprotein	104:115	arg1	Envelope glycoprotein	glycoprotein (g				OGER		glycoprotein (g	P07996		Envelope glycoprotein (g)B is conserved throughout the Herpesviridae and mediates fusion of the viral envelope with cellular membranes for infectious entry and spread.
32607666	2	80	gly	Cal+	354:357	arg1	Calcofluor-binding polysaccharides	Cal			Calcofluor-binding polysaccharides	OGER		Cal	Q9HD26		Its major surface glycopolymers consist of lipopolysaccharides (LPS) and Calcofluor-binding polysaccharides (Cal+ phenotype).
35164571	9	60	gly	PG	1662:1663	arg1	UDP-MurNAc-Ala	PG			UDP-MurNAc-Ala	Cterm		PG			YfiH selectively hydrolyzes UDP-MurNAc-Ser, an incorrect by-product of the biosynthesis reaction, to ensure that only the correct PG precursor, UDP-MurNAc-Ala, is incorporated.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND GlcA	TSP-3a			GlcA	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND Fuc	TSP-3a			Fuc	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND Ara	TSP-3a			Ara	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND Man	TSP-3a			Man	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND Rha	TSP-3a			Rha	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND GalN	TSP-3a			GalN	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32657144	3	65	gly	contained	785:793	arg1	TSP-3a AND Glc	TSP-3a			Glc	OGER		TSP	P07996		TSP-3a (758.6 kDa) mainly contained Man, GalN, GlcA, Rha, Glc, Gal, Ara, and Fuc in a molar ratio of 0.26:0.24:0.19:1.80:0.45:12.56:1.09:0.21.
32128391	0	35	gly	Glycosylation	0:12	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G	16059		Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases.
31915902	10	40	gly	N-glycoforms	1550:1561	arg1	IgG N-glycoforms	IgG N-glycoforms				Cterm		IgG			• BSA significantly changes IgG N-glycoforms as a medium additive.
33838822	5	21	gly	contained	792:800	arg1	MPS-1 AND glucose based sugar residues	MPS-1			glucose based sugar residues	OGER		However, MPS-1	P42677		However, MPS-1 contained glucose based sugar residues such as 3-Glcp and 4-Glcp which were not shown on MPS-2.
34925283	8	65	gly	N-glycosylation	1342:1356	arg1	Hbt	Hbt				OGER		Hbt	Q9Y6M7		Moreover, this study demonstrated how compromised N-glycosylation affects various facets of Hbt.
31915902	7	19	gly	N-glycoforms	1182:1193	arg1	IgG N-glycoforms	IgG N-glycoforms				Cterm		IgG			Together, our finding suggests that BSA increases the complexity of IgG N-glycoforms, thus raising the difficulty in maintaining glycoforms consistency during antibody production.
32349995	2	15	gly	Glycosylation	215:227	arg1	IgG	IgG				PUBTATOR		IgG	668542		Glycosylation of immunoglobulin G (IgG) is an important post-translation process affecting the inflammatory potential of IgG.
32349995	2	15	gly	Glycosylation	215:227	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G			Glycosylation of immunoglobulin G (IgG) is an important post-translation process affecting the inflammatory potential of IgG.
32649905	0	9	gly	Fucosylation	8:19	arg1	the Wnt Co-receptor LRP6	the Wnt Co-receptor LRP6				PUBTATOR		LRP6	O75581		In Situ Fucosylation of the Wnt Co-receptor LRP6 Increases Its Endocytosis and Reduces Wnt/β-Catenin Signaling.
32649905	0	40	gly	LRP6	44:47	arg1	In Situ Fucosylation	LRP6			In Situ Fucosylation	PUBTATOR		LRP6	O75581		In Situ Fucosylation of the Wnt Co-receptor LRP6 Increases Its Endocytosis and Reduces Wnt/β-Catenin Signaling.
32518941	7	20	gly	N-glycosylated	1121:1134	arg1	SARS-CoV-2	SARS-CoV-2				OGER		SARS	P49591		All 22 N-glycosylated sites of SARS-CoV-2 are modified by high-mannose N-glycans.
32518941	7	40	gly	modified	1160:1167	arg3	SARS-CoV-2 AND high-mannose N-glycans	SARS-CoV-2			high-mannose N-glycans	OGER		SARS	P49591		All 22 N-glycosylated sites of SARS-CoV-2 are modified by high-mannose N-glycans.
32518941	0	91	gly	glycoprotein	43:54	arg1	spike glycoprotein	spike glycoprotein				PUBTATOR		spike glycoprotein	43740568		Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics.
32637953	3	27	gly	glycosylated	449:460	arg1	The S protein	The S protein				OGER		S protein	Q15517		The S protein, like many other viral fusion proteins such as HIV-1 envelope (Env) and influenza hemagglutinin, is glycosylated with both complex and high mannose glycans.
33664475	2	23	gly	sialylated	203:212	arg1	HMOs	HMOs				OGER		HMOs	P00540		While sialylated human milk oligosaccharides (HMOs) have been implicated in phenotypic programming, their selective role and underlying mechanisms remained elusive.
32511307	4	45	gly	glycoprotein	731:742	arg1	the S glycoprotein	the S glycoprotein				Cterm		S glycoprotein	43740568		Lastly, we have identified peptides in the S glycoprotein that are likely to be presented in human leukocyte antigen (HLA) complexes, and discuss the role of S protein glycosylation in potentially modulating the adaptive immune response to the SARS-CoV-2 virus or to a related vaccine.
32511307	3	27	gly	glycoprotein	672:683	arg1	the S glycoprotein	the S glycoprotein				PUBTATOR		S glycoprotein	43740568		These models were subjected to molecular dynamics (MD) simulation to determine the extent to which glycan microheterogeneity impacts the antigenicity of the S glycoprotein.
34782210	6	4	gly	DP	984:985	arg1	galactooligosaccharides	DP 2-4			galactooligosaccharides	OGER		DP 2-4	Q14188		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	4	gly	DP	984:985	arg1	xylooligosaccharides	DP 2-4			xylooligosaccharides	OGER		DP 2-4	Q14188		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	4	gly	DP	984:985	arg1	food-grade fructooligosaccharides	DP 2-4			food-grade fructooligosaccharides	OGER		DP 2-4	Q14188		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	8	gly	DP	905:906	arg1	galactooligosaccharides	DP 3 and 4			galactooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	8	gly	DP	905:906	arg1	xylooligosaccharides	DP 3 and 4			xylooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	8	gly	DP	905:906	arg1	food-grade fructooligosaccharides	DP 3 and 4			food-grade fructooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	34	gly	DP	944:945	arg1	galactooligosaccharides	DP 3 and 4			galactooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	34	gly	DP	944:945	arg1	xylooligosaccharides	DP 3 and 4			xylooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
34782210	6	34	gly	DP	944:945	arg1	food-grade fructooligosaccharides	DP 3 and 4			food-grade fructooligosaccharides	PUBTATOR		DP 3 and 4	324		This approach is shown to work for the preparation of food-grade fructooligosaccharides of DP 3 and 4, galactooligosaccharides of DP 3 and 4, and xylooligosaccharides of DP 2-4.
32810535	8	12	gly	FGF2	1165:1168	arg1	GalNAc 4S	FGF2			GalNAc 4S	OGER		FGF2	P09038		GalNAc 4S of YG-1 could be the binding sites of FGF2 and FGFR.
32518941	1	14	gly	coat	227:230	arg1	their spike glycoproteins	spike glycoproteins			coat	PUBTATOR		spike glycoproteins	43740568		Coronaviruses hijack human enzymes to assemble the sugar coat on their spike glycoproteins.
32518941	1	76	gly	glycoproteins	247:259	arg1	their spike glycoproteins	their spike glycoproteins				PUBTATOR		spike glycoproteins	43740568		Coronaviruses hijack human enzymes to assemble the sugar coat on their spike glycoproteins.
34661088	3	20	gly	N-glycosylation	460:474	arg1	S1 protein	S1 protein				Cterm		S1 protein	Q15517		In this study, we investigated the effect of different N-glycosylation of S1 protein on its binding to ACE2.
33551170	11	72	gly	glycosylation	1917:1929	arg1	GlyCAM-1	GlyCAM-1				PUBTATOR		GlyCAM-1	282430		Overall, these data demonstrate that the glycosylation, and particularly fucosylation, of GlyCAM-1 was variable, although these shifts appear to be related more to individual cow variation than to nutrient supply.
32507236	6	0	gly	glycans	999:1005	arg1	Asn112			Asn112	Asn112		AminoAcid			Asn109 and Asn112	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32507236	6	0	gly	glycans	999:1005	arg1	Asn109			Asn109	Asn109		AminoAcid			Asn109 and Asn112	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32507236	6	0	gly	glycans	999:1005	arg1	Asn128			Asn128	Asn128		AminoAcid			Asn128	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32507236	6	39	gly	glycans	1032:1038	arg1	Asn112			Asn112	Asn112		AminoAcid			Asn109 and Asn112	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32507236	6	39	gly	glycans	1032:1038	arg1	Asn109			Asn109	Asn109		AminoAcid			Asn109 and Asn112	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32507236	6	39	gly	glycans	1032:1038	arg1	Asn128			Asn128	Asn128		AminoAcid			Asn128	Our results revealed 10 glycan compositions for salivary AZGP1, including core fucosylated glycans on Asn128 and sialylated glycans on Asn109 and Asn112.
32902634	4	3	gly	glycosylated	798:809	arg1	CEACAM1	CEACAM1				PUBTATOR		CEACAM1	634		We describe a simple, relatively inexpensive procedure in which standard commercial media is supplemented with 13C-enriched glucose to achieve labeling of all glycans plus all alanines of the N-terminal domain of the highly glycosylated protein, CEACAM1.
32921414	1	28	gly	glycoprotein	141:152	arg1	Podoplanin	Podoplanin				PUBTATOR		Podoplanin	10630		Podoplanin (PDPN) is a highly O-glycosylated glycoprotein that is utilized as a specific lymphatic endothelial marker under pathophysiological conditions.
32921414	1	34	gly	O-glycosylated	126:139	arg1	Podoplanin	Podoplanin				PUBTATOR		Podoplanin	10630		Podoplanin (PDPN) is a highly O-glycosylated glycoprotein that is utilized as a specific lymphatic endothelial marker under pathophysiological conditions.
32921414	2	38	part_of	residue	502:508	arg1	hPDPN	hPDPN		residue		PUBTATOR	AminoAcid	hPDPN	10630	Thr76 residue	We previously developed an anti-human PDPN (hPDPN) monoclonal antibody (mAb), clone LpMab-3, which recognizes the epitope, including both the peptides and the attached disialy-core-l (NeuAcα2-3Galβl-3 [NeuAcα2-6]GalNAcαl-O-Thr) structure at the Thr76 residue in hPDPN.
31915902	11	27	gly	N-glycoforms	1608:1619	arg1	IgG N-glycoforms	IgG N-glycoforms				Cterm		IgG			• BSA's skewing of IgG N-glycoforms should be considered in IgG production.
34661088	4	58	gly	de-N-glycosylated	655:671	arg1	de-N-glycosylated S1 proteins	de-N-glycosylated S1 proteins				Cterm		de-N-glycosylated S1 proteins	Q15517		Using real-time surface plasmon resonance assay the negative effects were demonstrated by the considerable increase of binding affinities of de-N-glycosylated S1 proteins produced from three different expression systems including baculovirus-insect, Chinese hamster ovarian and two variants of human embryonic kidney 293 cells.
32610141	5	2	gly	N-glycosylated	882:895	arg1	the N-glycosylated GRP94 variant	the N-glycosylated GRP94 variant				PUBTATOR		GRP94 variant	22027		We show in cells, human specimens, and mouse xenografts that proteome connectivity is restorable by inhibition of the N-glycosylated GRP94 variant.
33291979	2	101	part_of	Pasta	189:193	arg1	T1-T10	Pasta		T1-T10		OGER	SiteSequence	Pasta	Q9Y2W3	T1-T10	Pasta samples (T1-T10) having different proportions of rice flour (RF, 60-80%), wheat flour (WF, 40-12%), malted green gram flour (MGGF, 5 and 10%) and guar gum (GG, 1-3%) were prepared using a single screw extruder.
32355733	8	29	gly	P-glycoprotein	1179:1192	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Cisplatin-resistant variants were confirmed by higher half maximal inhibitory concentration (IC50) values and increased P-glycoprotein (ABCB1, P-gp) expression compared to A2780 cells.
32128391	2	1	gly	glycosylation	268:280	arg1	IgG	IgG				PUBTATOR		IgG	16059		Aberrant glycosylation of IgG has been observed in many diseases, but little is understood about the underlying mechanisms.
34248864	7	34	gly	O-antigen	1400:1408	arg1	LPS core biosynthesis activity encoding genes	O-antigen			LPS core biosynthesis activity encoding genes	Cterm		O-antigen			The transcriptome analysis also indicated that A. muciniphila was less affected by the environmental changes and was able to sustain its abundance in the presence of B. thetaiotaomicron while increasing the expression of LPS core biosynthesis activity encoding genes (O-antigen ligase, Lipid A and Glycosyl transferases) as well as ABC transporters.
33604750	0	42	gly	G11	50:52	arg1	Exopolysaccharide	G11			Exopolysaccharide	OGER		G11	P49842		Exopolysaccharide of Anoxybacillus pushchinoensis G11 has antitumor and antibiofilm activities.
34574138	9	7	gly	glycopeptides	1357:1369	arg1	CMP	CMP				OGER		CMP	P21941		Overall, this novel approach provides comprehensive characterization of CMP and CMP-derived peptides and glycopeptides, and it can be applied in future studies of product quality, digestive survival and bioactivity.
33677972	4	16	gly	fucosylated	668:678	arg1	total and fucosylated HMOs	total and fucosylated HMOs				OGER		HMOs	P00540		The amount of total and fucosylated HMOs were higher in secretor than non-secretor mothers, while Bifidobacterium genus were highly enriched in infants fed by non-secretor mothers.
31915902	4	77	gly	N-glycoforms	489:500	arg1	IgG N-glycoforms	IgG N-glycoforms				Cterm		IgG			Here, we studied the effects on IgG N-glycoforms of different components in hybridoma culture media, specifically compared bovine serum albumin (BSA) with other small molecules, using a matrix-assisted laser desorption/ionization quadrupole ion trap time-of-flight multistage mass spectrometry (MALDI-QIT-TOF MSn)-based approach.